MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2025.126976

Медицинская библиотека · Vaccine · 2025

Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.

Abaasa Andrew M, Kusemererwa Sylvia, Ankunda Violet, Ongaria Terry A, Nayiga Bernadette, Kakande Ayoub, Ssemwanga Deogratius, Kimbugwe Geofrey, Bosa Henry K, Woldemariam Yonas T, Kisakye Annet, Humphreys James, Worwui Archibald K, Cohuet Sandra, Mwenda Jason M, Elliott Alison M, Kaleebu Pontiano, Ruzagira Eugene

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

COVID-19 vaccines significantly reduce severe disease outcomes, but uncertainty remains about long-term protection. We investigated vaccine effectiveness (VE) against SARS-CoV-2 infection over extended periods in the World Health Organisation AFRO-MoVE network studies in Africa.

METHODS

Participants with COVID-19-like symptoms were recruited between 2023 and 2024 for a test-negative case-control study conducted across 19-healthcare centres in Uganda. Cases were symptomatic patients with any three of cough, sore-throat, coryza, among others, and PCR-confirmed SARS-CoV-2, while controls were SARS-CoV-2 PCR-negative. Vaccination was verified from vaccination cards, hospital-records, vaccination registry and self-reporting. VE was assessed through three measures: (a) Annual - patients vaccinated in the past 12-months regardless of dose vs those vaccinated >12-months before symptom onset plus unvaccinated; (b) Absolute - patients vaccinated in the past 12-months vs unvaccinated; and (c) Relative - patients vaccinated in the past 12-months vs those vaccinated >12-months before symptom onset. VE was calculated as 1- adjusted odds ratio for three patient groups based on days since the last dose; (1) <365, (2) 7-269 and (3) 270-364 while adjusting for age, sex, calendar-time and chronic conditions. The sensitivity analysis excluded patients that were previously infected with SARS-CoV-2.

FINDINGS: In total, 1371 patients, 56 % female were recruited. Of these, 173 were classified as cases, with 97 (56 %) fully vaccinated compared to 701 (59 %) controls, p = 0.830. The overall adjusted VE was moderate, 45 % to 59 %, and remained consistent across the annual, absolute and relative measures. Sensitivity analysis showed consistently lower VE (32 % to 38 %) across all measures.

INTERPRETATION: The results suggest that COVID-19 vaccination provides moderate protection against symptomatic SARS-CoV-2 infection up to 12-months after the last dose and highlight the importance of up-to-date vaccinations for high-risk individuals. The lack of clear COVID-19 seasonality in this and other African settings creates a challenge to selecting the optimal timing for annual vaccination.

Для цитирования: Abaasa Andrew M, Kusemererwa Sylvia, Ankunda Violet, Ongaria Terry A, Nayiga Bernadette, Kakande Ayoub, Ssemwanga Deogratius, Kimbugwe Geofrey, Bosa Henry K, Woldemariam Yonas T, Kisakye Annet, Humphreys James, Worwui Archibald K, Cohuet Sandra, Mwenda Jason M, Elliott Alison M, Kaleebu Pontiano, Ruzagira Eugene. Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.. Vaccine. 2025. DOI: 10.1016/j.vaccine.2025.126976.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.